TSC-100 is under clinical development by TScan Therapeutics and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I drugs for Myelodysplastic Syndrome have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TSC-100’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TSC-100 is under development for the treatment of blood cancers like acute myelocytic Leukemia, acute lymphocytic leukemia and myelodysplastic syndrome in patients receiving hematopoietic stem cell transplant therapy with the goal of preventing relapse, a high unmet need in this setting. It acts by targeting HA-1 antigen. The therapeutic candidate comprises of T cells engineered to express a TCR of interest which are mixed with a genome-wide library of target cell. The drug candidate is developed based on the TScan platform technology. It is administered by intravenous route.
TScan Therapeutics overview
TScan Therapeutics (TCR) provides life-changing T cell therapies for patients. It is headquartered in Boston, Massachusetts, the US.
For a complete picture of TSC-100’s drug-specific PTSR and LoA scores, buy the report here.